Long Focus Capital Management’s Anixa Biosciences ANIX Stock Holding History

Long Focus Capital Management’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-147,360	Closed	-$342K	–	100
2024 Q4	$342K	Sell	147,360 -18,341	-11%	-$57K	0.01%	96
2024 Q3	$522K	Hold	165,701	–	–	0.02%	92
2024 Q2	$366K	Hold	165,701	–	–	0.01%	93
2024 Q1	$517K	Hold	165,701	–	–	0.03%	88
2023 Q4	$643K	Hold	165,701	–	–	0.02%	97
2023 Q3	$542K	Hold	165,701	–	–	0.02%	97
2023 Q2	$530K	Hold	165,701	–	–	0.02%	94
2023 Q1	$713K	Hold	165,701	–	–	0.04%	93
2022 Q4	$704K	Hold	165,701	–	–	0.05%	87
2022 Q3	$815K	Hold	165,701	–	–	0.08%	78
2022 Q2	$507K	Buy	165,701 +50,000	+43%	+$158K	0.05%	86
2022 Q1	$317K	Buy	115,701 +94,404	+443%	+$277K	0.04%	94
2021 Q4	$63K	Buy	+21,297	New	+$86.1K	0.01%	102

Other funds holding ANIX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LNWTC

Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MWM

Mission Wealth Management Santa Barbara, California $4.86B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Long Focus Capital Management's ANIX Position: Q1 2025 in Review

Long Focus Capital Management sold out of Anixa Biosciences (ANIX) in Q1 2025, closing a stake of 147,360 shares — an estimated $342K sold.

Long Focus Capital Management first reported a position in ANIX in Q4 2021 and held it in 13 quarters. The position peaked at $815K in Q3 2022. 58 funds tracked by Wall St. Rank hold ANIX as of Q1 2025.

Long Focus Capital Management reported no remaining Anixa Biosciences position as of Q1 2025 after selling out during the quarter.
Long Focus Capital Management sold 147,360 Anixa Biosciences shares in Q1 2025, an estimated $342K.
Long Focus Capital Management first reported a position in Anixa Biosciences in Q4 2021 and held it in 13 quarters.
Long Focus Capital Management's Anixa Biosciences position peaked at $815K in Q3 2022.
58 funds tracked by Wall St. Rank held Anixa Biosciences as of Q1 2025.

Based on Long Focus Capital Management's 13F filing for Q1 2025, filed 15 May 2025.